These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 29120264)
21. Valbenazine for the treatment of tardive dyskinesia. Müller T Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695 [TBL] [Abstract][Full Text] [Related]
22. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia. Khorassani F; Luther K; Talreja O Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564 [TBL] [Abstract][Full Text] [Related]
23. Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia. Davis MC; Miller BJ; Kalsi JK; Birkner T; Mathis MV N Engl J Med; 2017 Jun; 376(26):2503-2506. PubMed ID: 28489481 [No Abstract] [Full Text] [Related]
24. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. Caroff SN; Aggarwal S; Yonan C J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423 [TBL] [Abstract][Full Text] [Related]
25. Clinical development of valbenazine for tics associated with Tourette syndrome. Farber RH; Angelov A; Kim K; Carmack T; Thai-Cuarto D; Roberts E Expert Rev Neurother; 2021 Apr; 21(4):393-404. PubMed ID: 33682568 [No Abstract] [Full Text] [Related]
26. Valbenazine in the treatment of tardive dyskinesia. Witek N; Comella C Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115 [TBL] [Abstract][Full Text] [Related]
27. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia. Kim AP; Baker DE; Levien TL Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698 [TBL] [Abstract][Full Text] [Related]
28. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia. Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946 [No Abstract] [Full Text] [Related]
29. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia. Dorfman BJ; Jimenez-Shahed J Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440 [No Abstract] [Full Text] [Related]
30. VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Harriott ND; Williams JP; Smith EB; Bozigian HP; Grigoriadis DE Prog Med Chem; 2018; 57(1):87-111. PubMed ID: 29680151 [TBL] [Abstract][Full Text] [Related]
31. Valbenazine (Ingrezza) for tardive dyskinesia. Med Lett Drugs Ther; 2017 May; 59(1521):83-84. PubMed ID: 28520698 [No Abstract] [Full Text] [Related]